IP Library Granted Patent US 10,669,327
Granted Patent B2
US 10,669,327 · App. 16/084,998 · Granted Jun 2, 2020

Methods of purifying collagen 7

Inventors: Igor Quinones-Garcia (Lexington, MA); Benjamin Simeone (Lexington, MA); Raymond Lillie (Lexington, MA); Ting Yang (Lexington, MA); David Nichols (Lexington, MA)
Assignee: PHOENIX TISSUE REPAIR, INC.
C07K14/78A61K38/39C07K1/16C07K1/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,669,327
App. No.
16/084,998
Granted
Jun 2, 2020
Kind
B2
Abstract

The present disclosure provides methods for capturing recombinant collagen 7 from cell culture and methods of purifying recombinant collagen 7. Also provided are compositions comprising purified recombinant collagen 7 that may be used for administration to humans.

Claims (49)

1. A method for capturing recombinant collagen 7 product from a cell culture, the method comprising:

a) subjecting a supernatant harvested from the cell culture to a depth filter, wherein the supernatant contains recombinant human collagen 7;

b) collecting a solution that flows through the depth filter;

c) subjecting the solution from step b) to an ultrafiltration step, wherein the recombinant human collagen 7 concentrates in a layer adjacent to an ultrafiltration membrane;

d) discarding a first retentate, wherein the first retentate comprises impurities contained in the solution from step b);

e) subjecting the layer adjacent to the ultrafiltration membrane to a solubilization agent and/or a surfactant to recover recombinant human collagen 7 and to obtain a second retentate comprising recombinant human collagen 7;

f) subjecting the second retentate to a diafiltration step to obtain an unpurified bulk liquid comprising recombinant collagen 7; and

g) optionally freezing the unpurified bulk liquid,

wherein the solubilization agent comprises at least one of urea, thiourea, arginine, butanol, ethanol, lithium perchlorate, lithium acetate, magnesium acetate, phenol, propanol, sodium dodecyl sulfate, aspartic acid, glutamic acid, ascorbic acid, glutamine, asparagine, and guanidine.

2. The method of claim 1 , further comprising before step a), the steps of:

I) culturing host cells that produce recombinant human collagen 7; and

II) harvesting supernatant from the cultured host cells.

3. The method of claim 2 , wherein the unpurified bulk liquid contains 40-80% of the recombinant human collagen 7 in the supernatant collected from step II).

4. The method of claim 3 , wherein the cell culture comprises culturing host cells in a bioreactor with a volume of at least 200 liters.

5. The method of claim 4 , wherein the bioreactor is a perfusion bioreactor or a fed-batch bioreactor.

6. The method of claim 5 , wherein the unpurified bulk liquid contains over 50 grams of recombinant human collagen 7.

7. The method of claim 1 , wherein the solubilization agent comprises arginine.

8. A method for purifying recombinant human collagen 7, the method comprising:

a) subjecting a sample containing recombinant human collagen 7 to a mixed mode, flow through resin, wherein the mixed mode, flow through resin comprises a ligand activated core and an inactive shell, wherein the inactive shell prevents recombinant human collagen 7 from entering the ligand activated core and wherein impurities that are small enough pass through the inactive shell and bind to the ligand activated core;

b) collecting a first effluent that flows through the mixed mode, flow through resin and contains recombinant human collagen 7;

c) subjecting the first effluent from step b) to a cation exchange chromatography resin under conditions permitting the recombinant human collagen 7 to bind to the cation exchange chromatography resin;

d) eluting recombinant human collagen 7 from the cation exchange chromatography resin;

e) subjecting the eluted recombinant human collagen 7 from step d) to a hydrophobic interaction chromatography resin in flow through mode and collecting a second effluent that flows through the hydrophobic interaction chromatography resin;

f) adding a solubilization agent and/or surfactant to the second effluent from step e) prior to step g);

g) subjecting the second effluent of step f) to an ultrafiltration step to concentrate the recombinant human collagen 7;

h) dialfiltering the concentrated recombinant human collagen 7 from step g) with a buffer comprising at least one salt, a solubilization agent, and a sugar; and

i) recovering purified recombinant human collagen 7,

wherein the method comprises one or more viral reduction steps and an endonuclease treatment step.

9. The method of claim 8 , wherein the ultrafiltration step comprises a tangential flow filter and wherein the tangential flow filter comprises a hydrophilic membrane.

10. The method of claim 8 , wherein the one or more viral reduction steps comprise a step of irradiating the sample containing recombinant human collagen 7 prior to step a), a step of adding a surfactant to the first effluent from step b), and a step subjecting the second effluent from step e) to a porous filter.

11. The method of claim 10 , wherein the endonuclease treatment step comprises treating the eluted recombinant human collagen 7 from step d) with an endonuclease.

12. The method of claim 8 , wherein the solubilization agent comprises at least one of urea, thiourea, arginine, butanol, ethanol, lithium perchlorate, lithium acetate, magnesium acetate, phenol, propanol, sodium dodecyl sulfate, aspartic acid, glutamic acid, ascorbic acid, glutamine, asparagine, and guanidine.

13. The method of claim 12 , wherein the at least one salt is one or more of sodium chloride, citrate, and sodium phosphate, the solubilization agent is arginine, and the sugar is sucrose.

14. The method of claim 13 , wherein the purified recombinant human collagen 7 of step i) contains on average between 15-30% of the amount of the recombinant human collagen 7 in the sample from step a).

15. The method of claim 14 , wherein the sample in step a) contains at least 25 grams of recombinant human collagen 7.

16. The method of claim 15 , wherein at least 4.0 grams of purified recombinant human collagen 7 is recovered in step i).

17. The method of claim 16 , wherein the purified recombinant human collagen 7 of step i) contains no more than 600 ng/mg.

18. The method of claim 17 , wherein the purified recombinant human collagen 7 of step i) contains no more than 15 pg/mg.

19. The method of claim 18 , wherein the purified recombinant human collagen 7 of step i) contains no more than 0.50 EU/mg.

20. The method of claim 19 , further comprising before step a), the steps of:

I) subjecting a supernatant harvested from a cell culture to a depth filter, wherein the supernatant contains recombinant human collagen 7;

II) collecting a solution that flows through the depth filter;

III) subjecting the solution from step b) to an ultrafiltration step, wherein the recombinant human collagen 7 concentrates in a layer adjacent to the ultrafiltration membrane;

IV) discarding a first retentate, wherein the first retentate comprises impurities contained in the solution from step II);

V) subjecting the layer adjacent to the ultrafiltration membrane to a solubilization agent and/or a surfactant to recover recombinant human collagen 7 and to obtain a second retentate comprising recombinant human collagen 7;

VI) subjecting the second retentate to a diafiltration step to obtain an unpurified bulk liquid comprising recombinant human collagen 7; and

VII) optionally freezing the unpurified bulk liquid,

wherein the solubilization agent comprises at least one of urea, thiourea, arginine, butanol ethanol lithium perchlorate, lithium acetate, magnesium acetate, phenol propanol sodium dodecyl sulfate, aspartic acid, glutamic acid, ascorbic acid, glutamine, asparagine, and guanidine.

21. The method of claim 20 , wherein the solubilization agent comprises arginine.

Assignments (7)
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL Recorded Mar 5, 2025
From: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: BRIDGEBIO PHARMA, INC.; QED THERAPEUTICS, INC.; EIDOS THERAPEUTICS, INC.; ML BIO SOLUTIONS INC.; CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.; VENTHERA, INC.; MOLECULAR SKIN THERAPEUTICS, INC.; CANTERO THERAPEUTICS, INC.; COA THERAPEUTICS, INC.; PORTAL THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; FERRO THERAPEUTICS, INC.
Reel/Frame 070551/0095 →
SECURITY INTEREST Recorded Jan 19, 2024
From: BRIDGEBIO PHARMA, INC.; QED THERAPEUTICS, INC.; EIDOS THERAPEUTICS, INC.; THERAS, INC.; ML BIO SOLUTIONS INC.; CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.; VENTHERA, INC.; MOLECULAR SKIN THERAPEUTICS, INC.; CANTERO THERAPEUTICS, INC.; COA THERAPEUTICS, INC.; PORTAL THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; FERRO THERAPEUTICS, INC.; SUB21, INC.
To: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 066355/0126 →
RELEASE OF SECURITY INTEREST Recorded Jan 18, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: BRIDGEBIO PHARMA, INC.; ORIGIN BIOSCIENCES, INC.; EIDOS THERAPEUTICS, INC.; QED THERAPEUTICS, INC.; ADRENAS THERAPEUTICS, INC.; PHOENIX TISSUE REPAIR, INC.
Reel/Frame 066167/0462 →
SECURITY INTEREST Recorded Jan 17, 2024
From: CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.; VENTHERA, INC.; MOLECULAR SKIN THERAPEUTICS, INC.; CANTERO THERAPEUTICS, INC.; COA THERAPEUTICS, INC.; PORTAL THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; FERRO THERAPEUTICS, INC.; SUB21, INC.
To: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 066342/0154 →
SECURITY INTEREST Recorded Nov 17, 2021
From: BRIDGEBIO PHARMA, INC.; ORIGIN BIOSCIENCES, INC.; EIDOS THERAPEUTICS, INC.; QED THERAPEUTICS, INC.; ADRENAS THERAPEUTICS, INC.; PHOENIX TISSUE REPAIR, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 058144/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2018
From: QUINONES-GARCIA, IGOR; SIMEONE, BENJAMIN; LILLIE, RAYMOND; YANG, TING; NICHOLS, DAVID
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 047291/0523 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2018
From: SHIRE HUMAN GENETIC THERAPIES, INC.; LOTUS TISSUE REPAIR, INC.
To: PHOENIX TISSUE REPAIR, INC.
Reel/Frame 047291/0591 →